A clinical trial is underway that may provide women with a more accurate way to detect cervical cancer.
The FDA has approved a new use against late-stage cervical cancer.
A long-term follow-up study shows the sustained efficacy, immunogenicity, and safety of GlaxoSmithKline's human papillomavirus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than 9 years, and vaccine efficacy (VE) against incident infection was 100%.
An HPV test alone may provide better reassurance against cervical cancer than the Pap test alone and similar reassurance to cotesting, according to a new study.
Researchers describe a novel approach to preventing cervical cancer. The study findings showed a reduction in cervical cancer risk after removal of a discrete population of cervical cells called squamocolumnar junction cells.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|